FOSTER CITY, Calif. - Gilead Sciences announced on Nov. 16 that it signed royalty-free voluntary licensing agreements with three generic drugmakers to prepare future access to its investigational antiviral obeldesivir across 127 countries. The agreements target primarily low- and lower-middle-income nations, including every African country reporting cases in the current Ebola Bundibugyo virus disease outbreak.
Manufacturing Readiness Ahead of Phase 3 Trial Results
The three licensed manufacturers are Dr. Reddy's Laboratories, Eva Pharma, and Ferozsons Laboratories, with technology transfer discussions already underway. If ongoing clinical studies succeed and regulators grant approval, the companies will be authorized to produce and supply obeldesivir as post-exposure prophylaxis for high-risk contacts. The drug is currently under evaluation in the ALIMA-coordinated Phase 3 EBO-PEP field trial and is not yet approved for any indication worldwide.
"Responding to emerging infectious diseases, including Ebola virus disease, requires not only scientific innovation, but also early planning and collaboration to help ensure that effective medicines can reach the people who need them as quickly as possible," said Jaime McCoy, vice president of Gilead Patient Solutions, in a company release.
Remdesivir Agreements Expanded Alongside Donations
Gilead is also updating existing remdesivir voluntary licenses to cover filovirus diseases, pending results from a World Health Organization-sponsored PARTNERS treatment trial and regulatory clearance. During the current outbreak, Gilead has donated more than 38,000 vials of remdesivir for compassionate use in the Democratic Republic of the Congo, Uganda, and Kenya, including over 2,000 vials sent to Kenya.



